Antipsychotics - Articles - Page 7

How To Prevent a Lethal Clozapine Side Effect

August 16, 2020

Gastric hypomotility is a common clozapine side effect that can develop into the potentially lethal condition of paralytic ileus. Dr. Aiken’s covered these risks in The Carlat Psychiatry Report. Here’s what you need to know.Dangers of Paralytic Ileus: Hypomotility is very common. Clozapine is the worst offender out of any...

A New Antipsychotic for Bipolar Depression

July 30, 2020

Chris Aiken, MD.

Chris Aiken, MD. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

An atypical antipsychotic with a novel mechanism shows promise in bipolar depression.

Cognitive Rehabilitation for Youth With Psychotic Disorders

May 14, 2020

Psychotic disorders in children and adolescents include a range of neuropsychiatric problems related to the multitude of underlying neurophysiological differences and the problems created by these differences. Chief among these are cognitive impacts. This interview helps outline and give guidance for managing these cognitive problems related to both psychosis and...

7 Clozapine Tips

April 8, 2020

We're supposed to move to clozapine after two failed antipsychotics in schizophrenia, but how many of us are really doing that? Not enough. Clozapine may be difficult to use, but it is life changing for many patients. Here we bring you 7 tips, from serum plasma levels to little-known side...

How to Choose an Antipsychotic in Schizophrenia

March 30, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.

The Psychopharmacology Algorithm Project

March 30, 2020

David Osser, MD

David Osser, MD

General Editor of the Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Residency Training Program and Associate Professor of Psychiatry at Harvard University. Dr. Osser has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.

Lumateperone and lemborexant

March 9, 2020

The antipsychotic lumateperone (Caplyta) and the hypnotic lemborexant (Dayvigo) are the newest in their class. Both of them claim to improve on the safety of older medications, and we look at the data to see how those claims hold up.

An Answer for Psychotic Depression

February 10, 2020

Randall Moore, MD.

Randall Moore, MD. Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Research tells us how to start meds, but rarely when to stop them. This study brings some needed answers on discontinuing antipsychotics after recovery from psychotic depression.

How And When To Come Off Medications

January 27, 2020

Antipsychotics. For some, long term use is best, for others, you need to keep it short. In this interview with Nassir Ghaemi we dig into the research to find some answers.Date Published: 1/27/20Duration: 27 minutes, 1 secondArticle Referenced: "Antipsychotic Maintenance: How Long Is Enough?", The Carlat Psychiatry Report, January 2020The...

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials.